Viking Therapeutics, Inc.
US ˙ NasdaqCM ˙ US92686J1060

SecurityVKTX / Viking Therapeutics, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Barclays Plc ownership in VKTX / Viking Therapeutics, Inc.

On May 15, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 0 shares of Viking Therapeutics, Inc. (US:VKTX) valued at $0 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 516,656 shares of Viking Therapeutics, Inc.. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD.

Barclays Plc has a history of taking positions in derivatives of the underlying security (VKTX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VKTX / Viking Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VIKING THERAPEUTICS COM 92686J106 0 -516,656 -100.00 0 -100.00
2026-02-13 2025-12-31 13F VIKING THERAPEUTICS COM 92686J106 516,656 55,849 12.12 18,176 50.08 0.0044
2026-03-31 2025-09-30 13F/A-3 VIKING THERAPEUTICS COM 92686J106 460,807 229,607 99.31 12,110 97.68 0.0026
2026-03-19 2025-09-30 13F/A-2 VIKING THERAPEUTICS COM 92686J106 103,131 -128,069 6,529 0.0017
2025-11-12 2025-09-30 13F VIKING THERAPEUTICS COM 92686J106 460,807 229,607 12,110 0.0026
2026-02-27 2025-06-30 13F/A-2 VIKING THERAPEUTICS COM 92686J106 231,200 -214,495 -48.13 6,127 -43.08 0.0014
2025-08-14 2025-06-30 13F/A-1 VIKING THERAPEUTICS COM 92686J106 231,200 -214,495 6 0.0014
2025-08-13 2025-06-30 13F VIKING THERAPEUTICS COM 92686J106 231,200 -214,495 6 0.0005
2026-03-17 2025-03-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 445,695 353,139 381.54 10,764 189.02 0.0031
2025-05-15 2025-03-31 13F VIKING THERAPEUTICS COM 92686J106 445,695 353,139 11 0.0031
2026-03-19 2024-12-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 92,556 -10,575 -10.25 3,724 -42.96 0.0010
2025-02-13 2024-12-31 13F VIKING THERAPEUTICS COM 92686J106 92,556 -10,575 4 0.0010
2026-03-31 2024-09-30 13F/A-2 VIKING THERAPEUTICS COM 92686J106 103,131 13,896 15.57 6,529 38.03 0.0017
2024-11-19 2024-09-30 13F/A-1 VIKING THERAPEUTICS COM 92686J106 103,131 13,896 7 0.0017
2024-11-15 2024-09-30 13F VIKING THERAPEUTICS COM 92686J106 103,131 13,896 7 0.0017
2026-03-23 2024-06-30 13F/A-1 VIKING THERAPEUTICS COM 92686J106 89,235 -59,368 -39.95 4,730 -61.18 0.0014
2024-08-14 2024-06-30 13F VIKING THERAPEUTICS COM 92686J106 89,235 -59,368 5 0.0014
2026-03-24 2024-03-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 148,603 -391,110 -72.47 12,185 21.32 0.0042
2024-05-15 2024-03-31 13F VIKING THERAPEUTICS COM 92686J106 148,603 -391,110 12 0.0042
2026-03-25 2023-12-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 539,713 17,791 3.41 10,044 73.86 0.0037
2024-02-15 2023-12-31 13F VIKING THERAPEUTICS COM 92686J106 539,713 17,791 10 0.0037
2026-03-26 2023-09-30 13F/A-1 VIKING THERAPEUTICS COM 92686J106 521,922 332,913 176.14 5,778 88.61 0.0036
2023-11-07 2023-09-30 13F VIKING THERAPEUTICS COM 92686J106 521,922 332,913 6 0.0036
2026-03-30 2023-06-30 13F/A-2 VIKING THERAPEUTICS COM 92686J106 189,009 8,130 4.49 3,064 1.73 0.0019
2023-09-20 2023-06-30 13F/A-1 VIKING THERAPEUTICS COM 92686J106 189,009 8,130 3 0.0019
2023-08-03 2023-06-30 13F VIKING THERAPEUTICS COM 92686J106 189,009 8,130 3 0.0019
2026-03-30 2023-03-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 180,879 142,664 373.32 3,012 738.72 0.0014
2023-05-04 2023-03-31 13F VIKING THERAPEUTICS COM 92686J106 180,879 142,664 3 0.0014
2026-03-30 2022-12-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 38,215 34,180 847.09 359 3,163.64 0.0002
2023-02-13 2022-12-31 13F VIKING THERAPEUTICS COM 92686J106 38,215 34,180 0 0.0002
2022-11-03 2022-09-30 13F VIKING THERAPEUTICS COM 92686J106 4,035 4,034 403,400.00 11 0.0000
2022-08-12 2022-06-30 13F VIKING THERAPEUTICS COM 92686J106 1 -11,429 -99.99 0 -100.00
2022-05-16 2022-03-31 13F VIKING THERAPEUTICS COM 92686J106 11,430 -71,602 -86.23 35 -90.84 0.0000
2022-02-23 2021-12-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 83,032 54,515 191.17 382 112.22 0.0001
2022-02-14 2021-12-31 13F VIKING THERAPEUTICS COM 92686J106 83,032 54,515 382 0.0000
2021-11-09 2021-09-30 13F VIKING THERAPEUTICS COM 92686J106 28,517 19,003 199.74 180 215.79 0.0001
2021-08-13 2021-06-30 13F VIKING THERAPEUTICS COM 92686J106 9,514 -72,283 -88.37 57 -88.97 0.0000
2021-05-13 2021-03-31 13F VIKING THERAPEUTICS COM 92686J106 81,797 27,952 51.91 517 70.63 0.0003
2021-02-11 2020-12-31 13F VIKING THERAPEUTICS COM 92686J106 53,845 -20,145 -27.23 303 -29.53 0.0002
2020-11-12 2020-09-30 13F VIKING THERAPEUTICS COM 92686J106 73,990 -43,951 -37.27 430 -49.41 0.0003
2020-08-12 2020-06-30 13F VIKING THERAPEUTICS COM 92686J106 117,941 41,035 53.36 850 136.77 0.0007
2020-05-13 2020-03-31 13F VIKING THERAPEUTICS COM 92686J106 76,906 -2,287 -2.89 359 -43.46 0.0003
2020-02-10 2019-12-31 13F VIKING THERAPEUTICS COM 92686J106 79,193 45,173 132.78 635 171.37 0.0004
2019-11-15 2019-09-30 13F/A-1 VIKING THERAPEUTICS COM 92686J106 34,020 -28,509 -45.59 234 -54.91 0.0001
2019-11-14 2019-09-30 13F VIKING THERAPEUTICS COM 92686J106 34,020 -28,509 234 54.1011
2019-08-14 2019-06-30 13F VIKING THERAPEUTICS COM 92686J106 62,529 45,264 262.17 519 201.74 0.0003
2019-05-15 2019-03-31 13F VIKING THERAPEUTICS COM 92686J106 17,265 5,618 48.24 172 93.26 0.0001
2019-02-14 2018-12-31 13F VIKING THERAPEUTICS COM 92686J106 11,647 -137,082 -92.17 89 -96.57 0.0001
2018-11-14 2018-09-30 13F VIKING THERAPEUTICS COM 92686J106 148,729 -90,224 -37.76 2,591 14.29 0.0018
2018-08-14 2018-06-30 13F VIKING THERAPEUTICS COM 92686J106 238,953 224,280 1,528.52 2,267 3,442.19 0.0019
2018-05-15 2018-03-31 13F VIKING THERAPEUTICS COM 92686J106 14,673 12,988 770.80 64 814.29 0.0000
2018-02-14 2017-12-31 13F VIKING THERAPEUTICS COM 92686J106 1,685 1,685 7 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2024-11-19 2024-09-30 13F/A VIKING THERAPEUTICS OPT Call 0 0 n/a n/a n/a
2026-03-31 2024-09-30 13F/A VIKING THERAPEUTICS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-11-15 2024-09-30 13F VIKING THERAPEUTICS OPT Call 0 0 n/a n/a n/a
2026-03-23 2024-06-30 13F/A VIKING THERAPEUTICS OPT Call 80,000 67.71 4,241 8.41 n/a n/a n/a
2024-08-14 2024-06-30 13F VIKING THERAPEUTICS OPT Call 80,000 4 n/a n/a n/a
2026-03-24 2024-03-31 13F/A VIKING THERAPEUTICS OPT Call 47,700 3,911 n/a n/a n/a
2024-05-15 2024-03-31 13F VIKING THERAPEUTICS OPT Call 47,700 4 n/a n/a n/a
2019-02-14 2018-12-31 13F VIKING THERAPEUTICS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2018-11-14 2018-09-30 13F VIKING THERAPEUTICS OPT Call 25,000 436 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-02-13 2025-12-31 13F VIKING THERAPEUTICS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2026-03-19 2025-09-30 13F/A VIKING THERAPEUTICS OPT Put 20,400 1,292 n/a n/a n/a
2026-03-19 2024-12-31 13F/A VIKING THERAPEUTICS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-02-13 2024-12-31 13F VIKING THERAPEUTICS OPT Put 0 0 n/a n/a n/a
2024-11-19 2024-09-30 13F/A VIKING THERAPEUTICS OPT Put 20,400 1 n/a n/a n/a
2026-03-31 2024-09-30 13F/A VIKING THERAPEUTICS OPT Put 20,400 1,292 n/a n/a n/a
2024-11-15 2024-09-30 13F VIKING THERAPEUTICS OPT Put 20,400 1 n/a n/a n/a
2019-02-14 2018-12-31 13F VIKING THERAPEUTICS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2018-11-14 2018-09-30 13F VIKING THERAPEUTICS OPT Put 253,200 4,411 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.